000			04181nam a22004575i 4500
999			_c88136 _d88136 _x1
001			88136
003			ES-MaUEC
005			20230207040624.0
007			cr nn 008mamaa
008			161216s2016 gw | s |||| 0|eng d
020			_a9783319426099
024	7		_a10.1007/978-3-319-42609-9 _2doi
040			_aES-MaUEC
050		4	_aRM301.25 _bF676 2016 EB
245	1	0	_aFormulating Poorly Water Soluble Drugs _cedited by Robert O. Williams III, Alan B. Watts, Dave A. Miller.
250			_a2nd ed. 2016.
260			_aCham, Switzerland _bSpringer _c2016
300			_a1 recurso en línea (XIV, 779 p.) _b210 ilustraciones, 84 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-7371 _v22
505	0		_aRoute-Specific Challenges in Delivery of Poorly Water Soluble Drugs -- Optimizing the Formulation of Poorly Water Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle Size Reduction Techniques -- Solubilized Formulations -- Injectable Formulations of Poorly Water Soluble Drugs -- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs -- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.
520			_aThe objective of this volume is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist�s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound�s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.
650	0	7	_aTecnología farmacéutica _0http://id.loc.gov/authorities/subjects/sh85100590 _0LocalZ _2embne _9161127
650	0	7	_aFarmacia _0LocalZ _2embne _9137891
650		7	_aMedicina _0comprobar BNE19900959047 _2embne _9405021
650		7	_aTecnología farmacéutica _0comprobar BNE20030698632 _2embne _9161127
650	0	7	_aCiencias biomédicas _0LocalZ _2embne _9143729
700	1		_aWilliams III, Robert O. _eeditor literario _9101601 _0Local
700	1		_aWatts, Alan B. _eeditor literario _9101602 _0Local
700	1		_aMiller, Dave A. _eeditor literario _9101603 _0Local
830		0	_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-7371 _v22 _0http://id.loc.gov/authorities/names/n2011180825 _9133175
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-42609-9zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319426099
907			_a.b12981400 _b10-10-17 _c08-03-17
942			_2lcc _cLE
945			_aRM301.25 F676 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11603240 _z06-04-17
988			_aEBOOK, EBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0